Short answer
Rapport Therapeutics, Inc. (RAPP) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$40M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$40M
- −49.4% YoY · +28.9% QoQ
- EPS (diluted)
- −$0.85
- −19.7% YoY · +28.6% QoQ
Source: XBRL data from the Rapport Therapeutics, Inc. (RAPP) Q3 2026 10-Q on SEC EDGAR. USD.
Rapport Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue: $0, consistent with no product sales; nine-month collaboration revenue $20.0M vs $0
- Operating margin: (100.0%) vs (100.0%) YoY, net loss $40.2M vs $26.9M
- Worst performance: RAP-219 R&D costs $17.5M, up $8.7M YoY, driven by Phase 3 development
- Cash, equivalents and short-term investments $395.0M; operating cash use $96.1M for nine months
- Outlook: Phase 3 FOS trials enrolling; expenses expected to increase substantially; funding projected through 2029
Risk Factors
- Newly expanded AI/ML risk: EU AI Act and emerging U.S. state laws could impose costly governance, transparency, monitoring and human-oversight requirements
- Most materially updated regulatory risk: FDA’s June 2026 draft guidance may permit one pivotal trial, but FDA retains discretion to require additional clinical data
- Privacy compliance exposure: GDPR penalties can reach €20 million or 4% of annual global revenues
- Near-term clinical risk: RAP-219 Phase 3 programs face delays from enrollment, safety, efficacy or regulatory requirements
- Financial risk: $172.5 million of 2.25% convertible senior notes mature in 2032
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Rapport Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.